Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
01:11pm, Tuesday, 19'th Apr 2022 Benzinga
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
3
0
0
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
11:48am, Tuesday, 05'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P
Why Is Acadia (ACAD) Up 1% Since Last Earnings Report?
03:30pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Acadia (ACAD) Up 1% Since Last Earnings Report?
12:47pm, Wednesday, 30'th Mar 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
9 Monster Stock Market Predictions: With Rallies' Highs In, Reversal May Be Next
04:43am, Monday, 28'th Mar 2022 Investing.com
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
03:07pm, Wednesday, 16'th Mar 2022 Benzinga
Upgrades
Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to year-ago quarter EPS of
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
12:15pm, Wednesday, 16'th Mar 2022
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! The post Wednesday Top Stock News: 8 Analyst Upgrades and
A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision
10:09am, Wednesday, 16'th Mar 2022 Benzinga
Pre-open movers
U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results from Jabil Inc. (NYSE
Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
09:05pm, Thursday, 10'th Mar 2022 Kwhen Finance
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA
04:50pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA
01:32pm, Thursday, 10'th Mar 2022
Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.
Acadia Pharmaceuticals receives August FDA action date for Nuplazid sNDA
03:59pm, Wednesday, 09'th Mar 2022 Seeking Alpha
The FDA has assigned Aug. 4, 2022 as the action date for Acadia Pharmaceuticals (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for Alzheimers disease psychosis.
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
01:30pm, Wednesday, 09'th Mar 2022 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The FDA’s Division of Psychiatry has also advised the company that it is planning to hold an Advisory Committee meeting in
Why Acadia Healthcare (ACHC) Stock Might be a Great Pick
10:32am, Tuesday, 08'th Mar 2022
Acadia Healthcare (ACHC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
11:20am, Monday, 07'th Mar 2022 Zacks Investment Research
Sector ETF report for FBT
